Effect of topical tranexamic on hemoglobi
Phase 3
- Conditions
- D68.32Hemorrhagia.Hemorrhagic disorder due to extrinsic circulating anticoagulants
- Registration Number
- IRCT20180625040232N2
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Age between 18-65 years
ASA class Not having coagulopathy
Exclusion Criteria
Need to embed Double J
Prediction of need to transfusion during surgery
Having dyscrasia
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin. Timepoint: Before surgery and 48 hours after surgery. Method of measurement: Blood sampling.
- Secondary Outcome Measures
Name Time Method Hospital stay days. Timepoint: Once, at the time of discharge. Method of measurement: Calculating hospital stay days from admission to discharge.;Stone free rate (SFR). Timepoint: Once, when leaving the operating room. Method of measurement: Using Portable Radiological Device (C-arm).
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tranexamic acid's hemostatic effects in percutaneous nephrolithotomy patients?
How does topical tranexamic acid compare to intravenous administration in reducing postoperative hemoglobin loss?
Which biomarkers correlate with response to tranexamic acid in anticoagulant-induced hemorrhagic disorders?
What adverse events are associated with topical tranexamic acid use in urological surgeries?
Are there combination therapies involving tranexamic acid that enhance hemostasis in D68.32 patients?